Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
- 1 August 2019
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 46, 116-125
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and ElaborationAnnals of Internal Medicine, 2015
- Utilization of Oncotype DX in an Inner City Population: Race or Place?International Journal of Breast Cancer, 2013
- Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysisThe Breast, 2013
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysisLaboratory Investigation, 2013
- 21‐Gene recurrence scoresCancer, 2011
- Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?Breast Cancer Research and Treatment, 2011
- The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic FeaturesCancer Investigation, 2010
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004